Company Overview of TransMolecular, Inc.
As of March 2011, TransMolecular, Inc. was acquired by Morphotek, Inc. TransMolecular, Inc. engages in discovering, developing, and commercializing therapies for glioma, metastatic brain tumors, and cancers. It offers TM601, a synthetic a polypeptide based on amino acid peptide derived from scorpion venom, which is used to treat cancer. The company was founded in 1996 and is based in Cambridge, Massachusetts.
840 Memorial Drive
Cambridge, MA 02139
Founded in 1996
Key Executives for TransMolecular, Inc.
TransMolecular, Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact TransMolecular, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.